参附注射液对维持性血液透析患者心率变异性的影响(1)
[摘要]目的 探讨参附注射液对维持性血液透析患者心率变异性的影响。方法 选取2016年10月～2018年6月我院收治的92例行维持性血液透析患者作为研究对象，根據随机数字表法分为对照组和研究组，每组各46例。对照组患者常规行降压、纠正钙磷代谢紊乱、贫血、甲状腺功能亢进等治疗，研究组在对照组基础上给予参附注射液联合治疗。比较两组治疗前后的血压及生化指标水平、心率变异性，心律失常总发生率。结果 治疗前，两组的收缩压(SBP)、舒张压(DBP)、血清肌酐(Scr)、血糖(Glu)、总胆固醇(Chol)、血清尿酸(UA)水平比较，差异无统计学意义(P>0.05)；两组治疗后的SBP和DBP水平低于治疗前，研究组治疗后的SBP和DBP水平低于对照组，差异均有统计学意义(P<0.05)；治疗后，研究组全部正常R-R间期的标准差(SDNN)、SDNN的均值(SDNNI)、每5 min R-R间期均值的标准差(SDANNI)、正常相邻R-R间期差值的均方根RMSSD、正常相邻R-R间期差值>50 ms的百分比(PNN50)水平均显著高于对照组及治疗前，差异有统计学意义(P<0.05)；研究组的心律失常总发生率显著低于对照组，差异有统计学意义(P<0.05)。结论 对维持性血液透析患者而言，参附注射液是一种安全可靠的治疗药物，可有效改善血压、生化指标及心率变异性，降低心律失常发生率，值得广泛应用推广。
[关键词]参附注射液；维持性血液透析；心率变异性；心律失常
[中图分类号] R459.5 [文献标识码] A [文章编号] 1674-4721(2019)4(a)-0095-04
[Abstract] Objective To explore the effect of Shenfu Injection on heart rate variability in maintenance hemodialysis patients. Methods Ninety-two patients with maintenance hemodialysis admitted to our hospital from October 2016 to June 2018 were selected as the study subjects， they were divided into control group and research group according to random number table method， 46 cases in each group. Patients in the control group were routinely treated with hypotension， correction of calcium and phosphorus metabolic disorders， anemia， hyperthyroidism， et al. The research group was treated with Shenfu Injection on the basis of the control group. The blood pressure， biochemical indexes， heart rate variability before and after treatment and total incidence of arrhythmia were compared between the two groups. Results Before treatment， there were no significant differences in SBP， DBP， serum creatinine (Scr)， blood sugar (Glu)， total cholesterol (Chol)， serum uric acid (UA) between the two groups (P>0.05). The levels of SBP and DBP in the two groups after treatment were lower than those before treatment， and the levels of SBP and DBP in the research group after treatment were lower than those in the control group， the differences were statistically significant (P<0.05). After treatment， the standard deviation of all normal R-R intervals (SDNN)， Mean of SDNN (SDNNI)， standard deviation of the mean of the R-R interval every 5 minutes (SDANNI)， mean square root of normal adjacent R-R interval difference (RMSSD)， the percentage of normal adjacent R-R interval difference > 50 ms (PNN50) in the research group were significantly higher than those in the control group and before treatment， the differences were statistically significant (P<0.05). The total incidence of arrhythmia in the research group was significantly lower than that in the control group， the difference was significant (P<0.05). Conclusion For maintenance hemodialysis patients， Shenfu Injection is a safe and reliable therapeutic drug， which can effectively improve blood pressure， biochemical indicators and heart rate variability， reduce the incidence of arrhythmia， and is worthy of wide application and promotion., 百拇医药(邹东媚 曾梅珍)
[关键词]参附注射液；维持性血液透析；心率变异性；心律失常
[中图分类号] R459.5 [文献标识码] A [文章编号] 1674-4721(2019)4(a)-0095-04
[Abstract] Objective To explore the effect of Shenfu Injection on heart rate variability in maintenance hemodialysis patients. Methods Ninety-two patients with maintenance hemodialysis admitted to our hospital from October 2016 to June 2018 were selected as the study subjects， they were divided into control group and research group according to random number table method， 46 cases in each group. Patients in the control group were routinely treated with hypotension， correction of calcium and phosphorus metabolic disorders， anemia， hyperthyroidism， et al. The research group was treated with Shenfu Injection on the basis of the control group. The blood pressure， biochemical indexes， heart rate variability before and after treatment and total incidence of arrhythmia were compared between the two groups. Results Before treatment， there were no significant differences in SBP， DBP， serum creatinine (Scr)， blood sugar (Glu)， total cholesterol (Chol)， serum uric acid (UA) between the two groups (P>0.05). The levels of SBP and DBP in the two groups after treatment were lower than those before treatment， and the levels of SBP and DBP in the research group after treatment were lower than those in the control group， the differences were statistically significant (P<0.05). After treatment， the standard deviation of all normal R-R intervals (SDNN)， Mean of SDNN (SDNNI)， standard deviation of the mean of the R-R interval every 5 minutes (SDANNI)， mean square root of normal adjacent R-R interval difference (RMSSD)， the percentage of normal adjacent R-R interval difference > 50 ms (PNN50) in the research group were significantly higher than those in the control group and before treatment， the differences were statistically significant (P<0.05). The total incidence of arrhythmia in the research group was significantly lower than that in the control group， the difference was significant (P<0.05). Conclusion For maintenance hemodialysis patients， Shenfu Injection is a safe and reliable therapeutic drug， which can effectively improve blood pressure， biochemical indicators and heart rate variability， reduce the incidence of arrhythmia， and is worthy of wide application and promotion., 百拇医药(邹东媚 曾梅珍)